Sugi Predict

Sugi Predict / Compounds / SCHEMBL1486797

SCHEMBL1486797

SCHEMBL1486797

O=C(O)[C@H](Cc1ccc(O)cc1)N(Cc1ccccc1)P(=O)(O)O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ANPEP P15144 3/20 0.48
▸ ERAP2 Q6P179 3/20 0.48
▸ ERAP1 Q9NZ08 2/20 0.48
▸ LAP3 P28838 1/20 0.48
▸ ENPEP Q07075 1/20 0.48
▸ CYP1A2 P05177 1/20 0.44
▸ SLC7A5 Q01650 1/20 0.43
▸ PTPN1 P18031 2/20 0.42
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MME P08473 2/20 0.40
▸ ECE1 P42892 1/20 0.40
▸ CPA1 P15085 1/20 0.40
▸ CPA2 P48052 1/20 0.40
▸ CPA4 Q9UI42 1/20 0.40
▸ MMP1 P03956 1/20 0.40
▸ MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1486794 1.00 ANPEP (0.48) ANPEPERAP2ERAP1LAP3ENPEP
SCHEMBL27799946 0.81 SLC7A5 (0.49) CYP1A2SLC7A5PTPN1FNTAFNTB
SCHEMBL9715671 0.81 CYP1A2 (0.46) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL958771 0.81 CYP1A2 (0.46) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL9715664 0.80 CYP1A2 (0.44) ANPEPERAP2LAP3CYP1A2SLC7A5
SCHEMBL9715674 0.80 CYP1A2 (0.44) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL9715672 0.80 CYP1A2 (0.44) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL962281 0.80 LAP3 (0.47) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL9715668 0.80 LAP3 (0.47) ANPEPERAP2ERAP1LAP3CYP1A2
SCHEMBL9715663 0.80 CYP1A2 (0.44) ANPEPERAP2LAP3CYP1A2SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3660040-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-06-18 — — EP disclosed
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2025-02-13 — — US disclosed
EP-3666792-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-12-18 — — EP disclosed
US-20240294596-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2024-09-05 — — US disclosed
WO-2024151615-A1 MRNA DISPLAY LIBRARIES AND METHODS OF USE THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-07-18 — — WO disclosed
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-10-05 — — US disclosed
EP-4210729-A2 INSULIN RECEPTOR PARTIAL AGONISTS Merck Sharp & Dohme LLC (US) 2023-07-19 — — EP disclosed
EP-3660041-B1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME LLC (US) 2023-04-19 — — EP disclosed
US-11351268-B2 FGF21 C-terminal peptide optimization INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2022-06-07 — — US disclosed
WO-2022055877-A2 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-03-17 — — WO disclosed
WO-2016049190-A1 INCRETIN-INSULIN CONJUGATES INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-03-31 — — WO disclosed
EP-2793932-A1 CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES Indiana University Research and Technology Corporation (US) 2014-10-29 — — EP disclosed
WO-2013096386-A1 CTP-BASED INSULIN ANALOGS FOR TREATMENT OF DIABETES INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2013-06-27 — — WO disclosed
EP-2443146-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS Indiana University Research And Technology Corporation (US) 2012-04-25 — — EP disclosed
WO-2011163473-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2011-12-29 — — WO disclosed
EP-2307037-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS Indiana University Research and Technology Corporation (US) 2011-04-13 — — EP disclosed
EP-2300037-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS Indiana University Research and Technology Corporation (US) 2011-03-30 — — EP disclosed
WO-2010148089-A1 GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2010-12-23 — — WO disclosed
WO-2009155258-A2 GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed
WO-2009155257-A1 GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351268-B2 FGF21 C-terminal peptide optimization FGF23, FGFR1, FGFR3 ANPEP 68/4885ERAP2 434/4885ERAP1 360/4885
US-20240294596-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 ANPEP 1192/4885ERAP2 1516/4885ERAP1 1717/4885
US-20250051416-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 ANPEP 1192/4885ERAP2 1516/4885ERAP1 1717/4885
US-20230310551-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 ANPEP 1192/4885ERAP2 1516/4885ERAP1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.